What is certolizumab pegol used for?

CIMZIA is a prescription medicine called a Tumor Necrosis Factor (TNF) blocker used in adults to: Lessen the signs and symptoms of moderately to severely active Crohn’s disease (CD) in adults who have not been helped enough by usual treatments. Treat moderately to severely active rheumatoid arthritis (RA)

What is certolizumab pegol made of?

It is made up of a monoclonal antibody, certolizumab, which has been ‘pegylated’ (attached to a chemical called polyethylene glycol). A monoclonal antibody is a protein that has been designed to recognise and attach to a specific structure in the body.

Who makes certolizumab pegol?

Certolizumab pegol, sold under the brand name Cimzia, is a biologic medication for the treatment of Crohn’s disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.

Why is certolizumab PEGylated?

PEGylation is widely used to improve drug pharmacokinetics and bioavailability. It has been demonstrated that PEGylation significantly increases the circulating half-life of Fab’ molecules,17 permitting a minimum dosing interval of 2 weeks for certolizumab pegol.

What is an adverse effect of certolizumab?

SIDE EFFECTS: See also Warning section. Fever, cough, sore throat, stuffy/runny nose, burning/painful/frequent urination, or joint pain may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.

What is the brand name for certolizumab?

The brand name of certolizumab pegol is Cimzia®. It is a biologic drug that is in a class of drugs called anti-TNFs or TNF blockers.

How long should you take CIMZIA?

Crohn’s disease, you’ll get your first injection, and then another injection 2 weeks later. Then, you’ll take the drug again 2 weeks after that. After those 3 doses, if your condition is responding to the drug, you’ll take Cimzia once every 4 weeks.

Is cimzia a good drug?

In clinical studies, Cimzia was more effective than a placebo (a treatment with no active drug) at reducing symptoms of Crohn’s disease. In one study, after 26 weeks of treatment: 37% of people who took Cimzia had reduced symptoms. 29% of people who took Cimzia were in remission (had few or no symptoms)

What is certolizumab pegol (Cimzia)?

Abstract Certolizumab pegol (Cimzia®) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab’) of a monoclonal antibody that has been conjugated to polyethylene glycol.

How many patients are enrolled in the certolizumab pegol study?

The estimated enrollment is 4,000 patients, consisting of patients on certolizumab pegol and control patients who are on any medication for CD apart from certolizumab pegol and who have never taken certolizumab pegol ( Table 5 ). Two Phase 2 studies with certolizumab pegol have been completed in patients with chronic plaque psoriasis.

What are the side effects of certolizumab pegol?

Certolizumab pegol is generally well tolerated, with upper respiratory tract infections, rash and urinary tract infections being among the most frequent adverse reactions. Thus, certolizumab pegol is an effective option for the management of these autoimmune diseases.

How effective is certolizumab pegol for the treatment of cervical disc disease?

In these studies, certolizumab pegol (as first- or subsequent-line therapy) reduced the severity of CD when used as an induction or maintenance therapy, and improved the signs/symptoms and slowed the radiographic progression of RA (with or without concomitant methotrexate), PsA and axSpA.